For sales

📢 Highlights from April 28 to May 02 in the world of pharma and healthcare! 🗞️👀

VYUHPHARMA (Clinical data, Phase 3) NEUROCRINE BIOSCIENCES Neurocrine Biosciences advances NBI-III7568 into Phase 3 as a potential treatment for adults with schizophrenia Henlius (Collaboration, commercialization) Henlius secures upfront $31M in Sandoz deal for HLX13 biosimilar, aiming to expand access in immuno-oncology SYNHALE THERAPEUTER Synhale Therapeutics expands pipeline with telaglenastat acquisition, advancing into Phase 2 for pulmonary hypertension (Acquisition) (FDA, NDA) novo nordisk Novo Nordisk's oral semaglutide 25 mg accepted for FDA review as first potential oral GLP-1 therapy for obesity All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.